MediLumine and MARS Bioimaging Announce Partnership

Mars Bioimaging and MediLumine announce a partnership to develop applications for small animal imaging and jointly announce the success of a pilot study using MediLumine’s contrast agents and the MARS color x-ray imaging system.

Prof Phil Butler displays the area of his wrist that was scanned as one of the first human images taken with the MARS scanner.
A 3D MARS image of a wrist with a watch showing part of the finger bones in white and soft tissue in red.

In this study, the MARS scanner simultaneously identified and quantified three MediLumine contrast agents, Fenestra VC, Mvivo Au, and Mvivo BIS in a phantom with vials of the contrast agents. The different contrast agents can be visualized in 3D and assigned different colors based on ability of MARS technology to detect differences in attenuation slopes and k-edge jumps.

A 3D image of a phantom filled with MediLumine’s contrast agents in different vials and scanned with MARS Bioimaging’s preclinical scanner.
Representative mass attenuation vs. energy of different materials illustrating how multiple contrast agents can be simultaneously identified and quantified. The different materials in the contrast agents can be measured based on differences in attenuation slopes and k-edge jumps. Each material is then assigned a different color for visualization.

The MARS scanner enables simultaneous visualization and quantification of contrast agents in vivo.

Different contrast agents simultaneously visualized and segmented in 3D
Different contrast agents simultaneously visualized (sagittal slice) and quantified

MediLumine and MARS will now work jointly on applications and related technical resources to facilitate small animal imaging research with contrast enhanced color x-ray imaging.

I'm really excited about this partnership as it combines the power of MARS quantitative imaging with the MediLumine's functional contrast agents. The combination of the two technologies greatly increases the opportunity for novel molecular imaging for pre-clinical researchers.

Anthony Butler
Director & CMO
Mars Bioimaging

Working with MARS Bioimaging unlocks the potential of color x-ray imaging by providing a means to visualize disease in ways not yet imagined. Contrast enhanced color x-ray imaging will become a powerful tool in understanding human diseases and advancing drug discovery programs internationally.

Stephen Marchant
CEO
MediLumine Inc.

About MediLumine Inc.

MediLumine is committed to providing high quality instruments, reagents and accessories to support preclinical imaging programs in the life sciences. MediLumine’s PRISM™ series of in vivo imaging systems are designed for preclinical monitoring of physiological changes in living systems for therapeutic discovery research in universities and pharmaceutical companies. MediLumine’s Fenestra® and Mvivo™ contrast agents for micro-CT Imaging provide image enhancement for various applications allowing scientists to monitor progression of functional liver diseases, quantify tumor burdens, track cells in vivo and perform preclinical angiography.  For more information refer to www.medilumine.com

About Mars BioImaging Ltd.

MARS Bioimaging is a New Zealand-based manufacturer of high-resolution color x-ray systems for preclinical and point-of-care imaging. They offer quantitative color x-ray imaging solutions for researchers, complete with 2D/3D visualisation and advanced image analysis tools. For more information refer to www.marsbioimaging.com

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

More To Explore